Long-term financial costs associated with prostate cancer treatment

December 21, 2006

The financial burden related to prostate cancer management over five years is substantial and sustained, according to a new study. Published in the February 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study reveals that the cumulative cost of prostate cancer is, on average, $42,570 over five years. Watchful waiting was the least expensive treatment while radiation and androgen deprivation therapy were the most expensive. The longitudinal study was the first to look at all related healthcare costs associated with all prostate cancer treatments cumulatively over time and for all ages and disease risks. The cost patterns also indicate that these therapies were appropriately utilized according to current guidelines for disease risk and age. Therefore some therapies are actually costly because they are being appropriately used for higher risk or older patients.

More than 200,000 men are diagnosed with prostate cancer every year in the United States, but the treatment options are controversial. For each treatment, questions about efficacy and concerns about life-altering adverse effects raise concerns about cost versus benefit. While studies often report immediate treatment costs, most ignore the impact of side effects and longer term considerations, such as relapse. Although age and individual risk play a role in treatment decisions, these are often not controlled for in cost studies. In addition, no studies compare the costs of all treatments.

Leslie S. Wilson, Ph.D., Department of Clinical Pharmacy, School of Pharmacy and School of Medicine of the University of California, San Francisco and co-investigators examined patterns of healthcare use over time and compared the interval costs of all prostate-related treatments over five and a half years of 4,553 newly diagnosed men stratified by age, risk, and ethnicity. For the first time, a study identified and included prostate cancer treatment failure and adverse effects that incur cost. "This unique demonstration of long-term cumulative costs is a particular strength of this paper," the authors write, "and should assist those making cost comparisons among treatment types."

The team of investigators found that prostate-related expenditures were substantial in the long-term and varied by treatment type, risk and age. In the first six months, the mean cost after treatment was $11,495 and was directly impacted by treatment type. Cost ranged from only $2,568 for watchful waiting to $24,204 for external beam radiation. This initial treatment choice was, not surprisingly, affected by a patient's age and disease risk. Not surprisingly, older, high risk patients often required more expensive therapies, such as external beam radiation and androgen deprivation therapy, while younger, lower risk patients often required the less expensive prostatectomy.

Subsequent annual cost was found to average $7,740 and ranged from $5,843 for watchful waiting to $12,590 for androgen deprivation therapy. Cumulative mean cost over 5.5 years for all risk groups was $42,570, with watchful waiting costing the least at $32,135 and androgen deprivation therapy costing the most at $69,244.

Overall, these results "demonstrate that prostate-related costs per person are substantial and sustained over time, and that the short-term treatment cost comparisons most commonly found in the literature are not truly reflective of the cost of treatment choices over the long-term," conclude Dr. Wilson and co-authors.
-end-
Article: "Cumulative Cost Pattern Comparison of Prostate Cancer Treatments," Leslie S. Wilson, Ross Tesoro, Eric P. Elkin, Natalia Sadetsky, Jeanette M. Broering, David M. Latini, Janeen DuChane, Reema R, Mody, Peter R. Carroll, CANCER; Published Online: December 21, 2006 (DOI: 10.1002/cncr.22433); Print Issue Date: February 1, 2006.

Wiley

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.